In the present study, we observed that lapatinib treatment significantly suppressed expression of ERRα within breast cancer cells; moreover, a higher ERRα expression was observed in resistant cancer cells, further confirming the effects of ERRα on breast cancer resistance to lapatinib. The gene discussed is ESRRA; the disease is breast carcinoma.